News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
QLT Inc. Climbs to Profit on Eligard Sales
February 19, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TORONTO, Feb 19 (Reuters) - QLT Inc swung to a fourth-quarter profit on Thursday, as rising sales of its Eligard prostate cancer treatment and gains on asset divestments more than offset falling sales of its Visudyne anti-blindness formula.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Business
Navigating Funding Freezes and AI Frontiers
June 20, 2025
·
1 min read
·
Lori Ellis
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
Podcast
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
June 18, 2025
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations
June 18, 2025
·
4 min read
·
Annalee Armstrong
